Review Article

Antiangiogenic Therapy for Patients with Recurrent and Newly Diagnosed Malignant Gliomas

Table 1

Bevacizumab for recurrent or newly malignant gliomas.

StudyAgentsPatientsRRMPFS6-PFSMSTRef.

Phase IIBevacizumab + irinotecan35 recurrent GBM57%6 months46%10.5 months[11]
Phase IIBevacizumab85 recurrent GBM28%4.2 months43%9.2 months
Bevacizumab + irinotecan82 recurrent GBM38%5.6 months50%8.7 months [12]
Phase IIBevacizumab48 recurrent GBM35%4 months29%7.7 months[13]
Phase II Bevacizumab + irinotecan23 recurrent GBM61%5.0 months30%10 months
9 recurrent AG67%7.5 months56%Not reached [28]
Phase IIBevacizumab + irinotecan33 recurrent AG61%7.5 months55%16.3 months[29]
Retrospective   Bevacizumab + SRT20 recurrent GBM50%7.3 months65%12.5 months   [30]
5 recurrent AG60%7.5 months60%16.5 months
RetrospectiveSRS + bevacizumab5.2 months11.2 months   [31]
SRS + other drugs 49 recurrent GBM2.1 months3.9 months
Phase IIBevacizumab + erlotinib25 recurrent GBM48%4.5 months28%10.5 months
32 recurrent AG31%5.9 months44%17.8 months [32]
Phase IIBevacizumab + RT/TMZ70 newly diagnosed GBM13.6 months88%19.6 months[14]
Phase IIBevacizumab + RT/TMZ125 newly diagnosed GBM13.8 months87% [15]
Phase IIAdjuvant bevacizumab125 newly diagnosed
+ irinotecan + TMZGBM 13.8 months 21.3 months [33]

RR: response rate; MPFS: median progression-free survival; 6-PFS: 6-month progression-free survival; MST: median overall survival time; GBM: glioblastoma multiforme; AG: anaplastic gliomas; SRT: stereotactic radiotherapy; SRS: stereotactic radiosurgery; RT: radiotherapy; TMZ: temozolomide.